Pyridoxal-5-phosphate derivatives as HIV integrase inhibitors

A compound of formula I

• wherein Cx is selected from the group consisting of —CH═O, —CH═N—OH and —CH(OCH2CH3)2,
• wherein R1 is selected from the group consisting of H, a straight alkyl group of 1 to 6 carbon atoms, a branched alkyl group of 3 to 6 carbon atoms, F, Cl, Br, I, —CN and —COOH,
• wherein R2 is selected from the group consisting of —COOH, —SO2NR3R4, —SO2R5, —CONR3R4 and —COR5,
• wherein R3 is selected from the group consisting of H, a straight alkyl group of 1 to 6 carbon atoms, and a branched alkyl group of 3 to 6 carbon atoms,
• wherein R4 is selected from the group consisting of H, a straight alkyl group of 1 to 6 carbon atoms, a branched alkyl group of 3 to 6 carbon atoms, a cycloalkyl group of 3 to 8 carbon atoms, adamantan-1-yl, —CH2CH2OH, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 1,2,3,4-tetrahydroquinolin-5-yl, isoquinolin-5-yl, isoazol-3-yl, 2-halogeno-phenyl, 3-halogeno-phenyl, 4-halogeno-phenyl (halogeno being F, Cl, Br or I), 1,4,5,6-tetrahydropyrimidin-2-yl, pyrimidin-2-yl, 2,6-dimethylpyrimidin-4-yl, thiazol-2-yl and a group of formula
• wherein R5 is selected from group consisting of aziridin-1-yl, azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, azocanyl (i.e., the azacycloalkanes, 3 to 8 member ring system) and morpholin-4-yl,
• wherein m is 0, 1, 2 or 3, wherein n is 0 or 1,
• provided that when Cx is —CH═O and R1 is H or m is 0, n cannot be 0,
• provided that when Cx is —CH═O, R1 is Cl, m is 1 and n is 0, R1 is in a position selected from the group consisting of the 3′, 4′ and 5′ position,
• provided that when Cx is —CH═O and R1 is —COOH, m is 1 and n is 0, R1 is in a position selected from the group consisting of the 2′ and 6′ position,
• provided that when Cx is —CH═O, R1 is Cl, m is 1, n is 1, and R2 is —COOH;
• R1 may not occupy the 3′ position when R2 occupies a position selected from the group consisting of 2′ and 4′ position, and;
• R1 may not occupy the 2′ position when R2 occupies a 5′ position.